Telomir Pharmaceuticals, Inc. (TELO)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Telomir Pharmaceuticals, Inc. (TELO) trades at $1.23 with AI Score 48/100 (Grade C). Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on developing therapeutic treatments for human stem cells. Market cap: $42.29M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for TELO: TELO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TELO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TELO: the 1 perspectives are evenly split.
How is this calculated? →Telomir Pharmaceuticals, Inc. (TELO) Healthcare & Pipeline Overview
Telomir Pharmaceuticals, Inc. is a pre-clinical biotechnology firm developing TELOMIR-1, a novel small molecule targeting age-related inflammatory conditions. The company aims to commercialize therapeutic treatments for human stem cells, positioning itself within the competitive biotechnology landscape with a focus on innovative interventions.
What Is the Investment Thesis for TELO?
Telomir Pharmaceuticals, Inc. presents a high-risk, high-reward investment opportunity characteristic of pre-clinical-stage biotechnology companies. The core value driver is the successful development and commercialization of TELOMIR-1, their lead candidate targeting age-related inflammatory conditions. Positive pre-clinical data and subsequent successful clinical trials are critical for value appreciation. Key catalysts include the initiation of Phase 1 clinical trials for TELOMIR-1 and potential partnerships with larger pharmaceutical companies. The company's small market capitalization of $42.29M reflects its early stage, offering substantial upside potential if TELOMIR-1 demonstrates efficacy and safety. However, the investment is subject to significant risks, including clinical trial failures, regulatory hurdles, and the need for substantial additional funding.
Based on FMP financials and quantitative analysis
TELO Key Highlights
- Telomir Pharmaceuticals is a pre-clinical stage company, indicating a high-risk, high-reward profile.
- The company's lead candidate, TELOMIR-1, targets age-related inflammatory conditions, addressing a significant market need.
- The company rebranded from Metallo Therapies Inc. in October 2022, signaling a strategic shift.
- The company has a small market capitalization of $42.29M, reflecting its early stage.
- Beta of -0.73 suggests the stock price is less volatile than the market.
Who Are TELO's Competitors?
TELO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ANAB AnaptysBio, Inc. | $65.78 | -2.30% | $2.84B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $23.12 | +4.69% | $2.05B | 79 |
| ABCL AbCellera Biologics Inc. | $7.69 | -2.29% | $2.35B | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $3.95 | +0.25% | $372.56M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $24.32 | +4.58% | $1.58B | 68 |
| AXSM Axsome Therapeutics, Inc. | $252.48 | +4.07% | $12.99B | 68 |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | +0.00% | $416.12M | 68 |
| MIRM Mirum Pharmaceuticals, Inc. | $128.31 | +5.25% | $6.44B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TELO's Key Strengths?
- Novel therapeutic approach targeting stem cells.
- Focus on age-related inflammatory conditions with significant market potential.
- Proprietary small molecule (TELOMIR-1).
- Experienced management team.
What Are TELO's Weaknesses?
- Pre-clinical stage with no approved products.
- Limited financial resources.
- Small team size.
- High dependence on the success of TELOMIR-1.
What Could Drive TELO Stock Higher?
- Initiation of Phase 1 clinical trials for TELOMIR-1.
- Pre-clinical data releases demonstrating the efficacy of TELOMIR-1.
- Securing strategic partnerships with pharmaceutical companies.
- Advancing research and development efforts to expand the pipeline.
What Are the Key Risks for TELO?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for TELOMIR-1.
- Regulatory delays or rejection of TELOMIR-1.
- Competition from established pharmaceutical companies.
- Need for additional funding and potential dilution.
- Intellectual property challenges or infringement.
What Are the Growth Opportunities for TELO?
- Advancement of TELOMIR-1 through Clinical Trials: The successful completion of pre-clinical studies and the subsequent initiation and progression through Phase 1, Phase 2, and Phase 3 clinical trials represent a significant growth opportunity for Telomir Pharmaceuticals. Positive clinical data demonstrating the safety and efficacy of TELOMIR-1 in treating age-related inflammatory conditions could lead to substantial increases in the company's valuation. The timeline for this growth opportunity extends over the next 3-5 years, contingent on regulatory approvals and funding.
- Expansion into New Therapeutic Areas: Telomir Pharmaceuticals can leverage its expertise in stem cell therapeutics to expand its pipeline into new therapeutic areas beyond age-related inflammatory conditions. This could include developing treatments for other diseases characterized by inflammation or cellular dysfunction. The market size for novel therapeutics is substantial, with significant unmet needs in areas such as autoimmune diseases and neurodegenerative disorders. This expansion could occur within the next 5-7 years, requiring additional research and development efforts.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions can provide Telomir Pharmaceuticals with access to additional funding, expertise, and resources. These partnerships can accelerate the development and commercialization of TELOMIR-1 and other pipeline candidates. The timeline for securing such partnerships is ongoing, with potential deals materializing within the next 1-3 years. Successful partnerships could significantly de-risk the company's development programs.
- Intellectual Property Protection: Securing and maintaining strong intellectual property protection for TELOMIR-1 and other pipeline candidates is crucial for protecting the company's competitive advantage. This includes obtaining patents for the composition of matter, methods of use, and manufacturing processes. Strong IP protection can attract potential partners and investors, enhancing the company's long-term growth prospects. The ongoing effort to strengthen and defend its IP portfolio is a continuous growth opportunity.
- Commercialization and Market Entry: Upon successful completion of clinical trials and regulatory approvals, Telomir Pharmaceuticals will have the opportunity to commercialize TELOMIR-1 and enter the market. This could involve building its own sales and marketing infrastructure or partnering with a larger pharmaceutical company for commercialization. The market size for treatments for age-related inflammatory conditions is substantial, with significant revenue potential for a successful product. The timeline for commercialization is dependent on clinical trial outcomes and regulatory timelines, potentially occurring within the next 5-7 years.
What Opportunities Does TELO Have?
- Successful clinical trials leading to regulatory approval.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
- Growing market for age-related therapies.
What Threats Does TELO Face?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Need for additional funding and potential dilution.
What Are TELO's Competitive Advantages?
- Proprietary small molecule (TELOMIR-1) targeting a specific inflammatory pathway.
- Intellectual property protection through patents.
- First-mover advantage in developing stem cell therapeutics for specific conditions.
- Potential for strong clinical data to create a barrier to entry.
What Does TELO Do?
Telomir Pharmaceuticals, Inc., established in 2021 and headquartered in Baltimore, Maryland, is a pre-clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutic treatments for human stem cells. Originally named Metallo Therapies Inc., the company rebranded to Telomir Pharmaceuticals, Inc. on October 10, 2022, marking a strategic shift towards its current focus. The company's primary asset is TELOMIR-1, a novel small molecule designed as an oral in situ therapeutic intervention. TELOMIR-1 is being developed to address age-related inflammatory conditions such as hemochromatosis and osteoarthritis. Additionally, it is being explored for its potential in post-chemotherapy recovery by targeting and disrupting interleukin-17 induced inflammatory pathways. As a pre-clinical company, Telomir Pharmaceuticals is currently focused on research and development activities, with the goal of advancing TELOMIR-1 through clinical trials and ultimately to market. The company's strategy involves targeting specific inflammatory pathways to provide therapeutic benefits in areas with significant unmet medical needs. With a small team, Telomir Pharmaceuticals is concentrating its efforts on preclinical studies and strategic partnerships to advance its pipeline.
What Products and Services Does TELO Offer?
- Develops therapeutic treatments for human stem cells.
- Focuses on age-related inflammatory conditions.
- Creates novel small molecules for therapeutic intervention.
- Targets interleukin-17 induced inflammatory pathways.
- Aims to provide oral in situ therapeutic interventions.
- Conducts pre-clinical research and development.
How Does TELO Make Money?
- Develops and patents novel therapeutic molecules.
- Conducts pre-clinical and clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- Potentially commercializes approved therapies through partnerships or direct sales.
What Industry Does TELO Operate In?
Telomir Pharmaceuticals operates within the competitive biotechnology industry, characterized by rapid innovation and high regulatory hurdles. The market for age-related inflammatory conditions is substantial and growing, driven by an aging global population. Companies like Novartis and Pfizer are major players in this space, developing treatments for diseases such as osteoarthritis and inflammatory disorders. Telomir Pharmaceuticals aims to differentiate itself through its focus on stem cell therapeutics and its novel small molecule, TELOMIR-1. The success of companies in this sector depends on robust research and development, successful clinical trials, and strategic partnerships.
Who Are TELO's Key Customers?
- Pharmaceutical companies seeking to license or acquire novel therapeutics.
- Patients suffering from age-related inflammatory conditions.
- Healthcare providers prescribing treatments for inflammatory diseases.
- Potential partners for commercialization and distribution.
TELO Valuation & Market Position
With a $42.29M market cap, Telomir Pharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, TELO's quantitative score of 48/100 is below the peer average of 76/100.
FY2026 estForward Outlook
Wall Street analysts project Telomir Pharmaceuticals, Inc. revenue of about $1.5M for fiscal 2026, with EPS near $-0.28.
F-Score 2/9Financial Health
Telomir Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 17.78 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Its free cash flow yield is -10.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.00 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -21.1%, the inverse of the P/E and a quick read on earnings relative to price.
TELO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Insiders seem to be positioning themselves favorably, which often signals confidence in the company's prospects. Recent activity suggests they believe in TELO's long-term potential.
- The community is buzzing with optimism regarding upcoming trial results; the general feeling is that TELO is on the verge of a breakthrough.
- There's a growing narrative that TELO is undervalued relative to its peers in the longevity space. This perception could drive increased investor interest.
- The market seems to be responding positively to recent news, indicating a shift in sentiment towards TELO's strategic direction.
Bear Case
- The longevity sector is notoriously speculative, and TELO is no exception. A lot of the current excitement hinges on unproven therapies.
- Community sentiment can be fickle; positive buzz can quickly turn negative if trial results disappoint or if competitors release compelling data.
- Despite recent market gains, there's still a lingering concern about TELO's cash runway. Funding questions could dampen enthusiasm.
- The company's relatively small size makes it vulnerable to market volatility and larger industry trends. External factors could easily derail its progress.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TELO Latest News
No recent news available for TELO.
TELO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TELO.
Price Targets
Wall Street price target analysis for TELO.
TELO MoonshotScore
What does this score mean?
The MoonshotScore rates TELO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Erez Aminov
CEO
Erez Aminov serves as the CEO of Telomir Pharmaceuticals, Inc. His background includes experience in managing and leading companies, though specific details on his prior roles and education are not available. As CEO, he is responsible for overseeing the company's strategic direction, operations, and financial performance. His leadership is crucial for guiding Telomir Pharmaceuticals through its pre-clinical development stages and towards potential clinical trials.
Track Record: As the CEO of Telomir Pharmaceuticals, Erez Aminov has been instrumental in guiding the company's focus on developing TELOMIR-1. Specific achievements and milestones under his leadership are not detailed in the provided data. His role involves securing funding, managing the research and development process, and building relationships with potential partners and investors.
Common Questions About TELO (Healthcare)
What does Telomir Pharmaceuticals, Inc. Common Stock do?
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage biotechnology company focused on developing therapeutic treatments for human stem cells. Their lead candidate, TELOMIR-1, is a novel small molecule designed to target age-related inflammatory conditions, such as hemochromatosis and osteoarthritis. The company aims to commercialize TELOMIR-1 as an oral in situ therapeutic intervention, potentially offering a new approach to managing these conditions and improving post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways.
What do analysts say about TELO stock?
As a pre-clinical-stage company, Telomir Pharmaceuticals, Inc. does not have extensive analyst coverage. The stock's valuation is primarily based on the potential of TELOMIR-1 and the company's ability to advance it through clinical trials. Investors should carefully consider the risks associated with pre-clinical-stage companies, including the possibility of clinical trial failures and the need for additional funding. The company's small market capitalization reflects its early stage and the inherent uncertainties in drug development.
What are the main risks for TELO?
The primary risks for Telomir Pharmaceuticals, Inc. revolve around the successful development and commercialization of TELOMIR-1. Clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies pose significant challenges. The company's limited financial resources and small team size also present risks. Additionally, the need for additional funding could lead to dilution of existing shareholders. Investors should be aware of these risks before investing in TELO.
What are the key factors to evaluate for TELO?
Telomir Pharmaceuticals, Inc. (TELO) holds an AI score of 48/100 (low). Not financial advice.
How frequently does TELO data refresh on this page?
TELO prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TELO's recent stock price performance?
Telomir Pharmaceuticals, Inc. (TELO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel therapeutic approach targeting stem cells. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TELO overvalued or undervalued right now?
Valuing Telomir Pharmaceuticals, Inc. (TELO) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying TELO?
Before investing in Telomir Pharmaceuticals, Inc. (TELO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available for a pre-clinical stage company.
- Financial metrics are current as of the latest available data.